Clinical Trial Update: Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating erlotinib with or without investigational drug CS-7017 in advanced non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CS-7017
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Advanced Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Status: COMPLETED | Results posted: 2020-06-16